Targeting Inflammation for Endometrial Cancer Prevention
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Endometrial Carcinoma
- Sponsor
- Mayo Clinic
- Enrollment
- 191
- Locations
- 2
- Primary Endpoint
- Levels of eicosanoids and specialized pro-resolving mediators (SPMs) in visceral adipose tissue (VAT)
- Status
- Active, not recruiting
- Last Updated
- 4 months ago
Overview
Brief Summary
This study examines risk assessment and identifies prevention strategies for endometrial cancer. Collecting samples of blood and urine and risk assessments from patients with benign conditions or endometrial cancer may help doctors learn if there is a relationship between chronic inflammation and increase in risk for endometrial cancer.
Detailed Description
PRIMARY OBJECTIVE: I. To develop a model for a biobank that can be expanded across the Mayo Enterprise and implemented at extramural collaborative sites, including underserved populations. OUTLINE: This is an observational study. Patients complete a risk factor questionnaire over 15 minutes. Patients also undergo collection of blood and urine during pre-operative visit and collection of tissue samples at the time of surgery.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women over the age of 18 years old undergoing hysterectomy for any benign indication or endometrial cancer
Exclusion Criteria
- •Women under the age of 18 years
- •Women with a history of cancer, except for endometrial cancer or non-melanoma skin cancer
- •Women with type 1 diabetes
- •Women that have received radiation or chemotherapy for cancer
Outcomes
Primary Outcomes
Levels of eicosanoids and specialized pro-resolving mediators (SPMs) in visceral adipose tissue (VAT)
Time Frame: Through study completion, up to 24 weeks
Will compare eicosanoid and SPM levels by case-control status (women with endometrial carcinoma and women with non-cancerous conditions) in all patients with linear models, adjusted for age and body mass index (BMI) (and menstrual date, if needed).
Secondary Outcomes
- Ribonucleic acid (RNA) expression pathways related to inflammation in VAT(Through study completion, up to 24 weeks)